May 15, 2018—A broad coalition of patient and consumer advocacy groups urged congressional leaders yesterday to join them “in supporting, not weakening, the 340B program.” The 61 groups made the appeal as Congress debates a variety of proposals to alter the program and on the eve of a Senate committee hearing this morning on the drug discount program. In their May 14 letter, … [Read more...]
Report: 340B Hospitals Provide Far More Care for Low-Income Patients than Other Hospitals
March 13, 2018—On the eve of an important U.S. Senate hearing on the 340B drug discount program, a new report concludes hospitals in the program treat significantly more low-income patients, provide more uncompensated and unreimbursed care, and are more likely to offer low-income patients the types of critical specialized services that often are not fully … [Read more...]
Flaws in Understanding Intent of 340B Program Lead to Incomplete Conclusions in Study
January 25, 2018—A recent study published in the New England Journal of Medicine (NEJM)[i] suggests that hospital use of the 340B program is “contrary to the goals of the program,” relying on a finding that there is no evidence of hospitals using 340B savings to expand care or lower mortality among low-income patients. This finding is inconsistent with existing research that … [Read more...]
Senator, Patient Advocate Support 340B in Hearing
December 13, 2017—Members of the Senate Health, Education, Labor, and Pensions (HELP) Committee heard a powerful defense of the 340B drug discount program yesterday at a hearing on the new National Academies of Sciences (NAS) report on why medicines cost so much and what can be done about it. The committee’s senior Democratic member, Sen. Patty Murray (D-Wash.), noted that … [Read more...]